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Sirolimus reduces polycystic 
liver volume in patients with 
polycystic kidney disease
Proliferation of the biliary epithelium is significant and 
phospho-mammalian target of rapamycin expression is 
elevated in the polycystic liver of persons with autosomal 
dominant polycystic kidney disease (ADPKD; Figure). 
Because sirolimus inhibits a mammalian target of rapamycin, 
the authors of a recent study hypothesize that sirolimus may 
benefit patients with ADPKD.
Qian et al. looked at patients who received a kidney trans-
plant at the Mayo Clinic between 2001 and 2006 and com-
pared sirolimus–mycophenolate mofetil–prednisone with 
tacrolimus–mycophenolate mofetil–prednisone. Of the 116 
subjects who completed the randomized trial, 16 had radio-
logic studies that allowed the authors to assess changes in cyst 
volume following initial exposure to sirolimus or tacrolimus. 
Treatment with the sirolimus regimen was associated with an 
11.9% reduction in polycystic liver volume. Treatment with 
tacrolimus for a comparable duration was associated with 
a 14.1% increase. More reduction in native kidney volume 
was also noted in the sirolimus group as compared with the 
tacrolimus group. This represents very early evidence that 
sirolimus affects liver cystic volume. Evidence does not exist 
validating this radiologic measurement as an intermediate 
marker. So, while this study may serve as a foundation for 
investigating future therapeutic strategies, the immediate 
clinical application of these results is not clear. (J Am Soc 
Nephrol 2008; 19: 631–638; doi:10.1681/ASN.2007050626)
Lynda Szczech
Patients with septic shock 
given vasopressin versus 
norepinephrine infusion
Acute renal failure is undoubtedly a marker of extreme ill-
ness that complicates the management of patients with criti-
cal illnesses. Preventing acute renal failure in patients with 
hemodynamic instability would be of considerable benefit 
to them.
In a multicenter trial, Russell et al. randomized patients 
with septic shock who were given a minimum of 5 µg of nor-
epinephrine per minute to receive either low-dose vasopressin 
or norepinephrine. The primary end point was mortality at 
28 days; however, many secondary end points, including 
organ failure, were also examined.
The total of 778 patients in both arms did not show sig-
nificant difference in 28-day mortality rates (35.4% in the 
vasopressin arm versus 39.3% in the norepinephrine arm, 
P = 0.26). Similarly, little difference was found in the number 
of patients requiring renal replacement therapy (23 versus 25, 
P = 0.64). Patients with less severe septic shock in the vaso-
pressin group demonstrated lower mortality at 28 days (26.5% 
versus 35.7%, P = 0.05), but data on the frequency of renal 
replacement therapy in this group were not presented. The 
authors appropriately caution against the overinterpretation 
of these results given their meager significance in the setting 
of multiple comparisons.
Norepinephrine is thought of as the last-resort vasopressor. 
Vasopressin previously had been thought to hold promise 
for those with severe septic shock. These data do not sol-
idly demonstrate a difference between the two treatments 
in patient survival or lack of renal failure. If a benefit for 
overall mortality exists among those with less severe shock 
who receive vasopressin, no subsequent benefit in renal out-
comes is known. Until further research confirms the benefits 
of vasopressin based on severity of shock, these data do not 
support its preferential use over norepinephrine to preserve 
kidney function. (N Engl J Med 2008; 358: 877–887)
Lynda Szczech
Tight blood glucose control 
provides renoprotection in 
critically ill patients
A new study combines the data sets from two large clinical 
trials that both independently demonstrated the benefit of 
Phospho-mammalian target of rapamycin expression is elevated in 
polycystic liver disease.
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intensive insulin therapy (IIT) for kidney function in criti-
cally ill patients with acute kidney injury. This analysis offers 
more insight into the end points than the studies themselves 
because of the greater power afforded by both data sets.
The two trials randomized subjects with acute kidney injury 
to IIT or conventional insulin treatment.1,2 The IIT group 
received insulin infusion titrated to achieve blood glucose 
levels between 80 and 100 mg/dl. The conventional treat-
ment group received insulin infusion begun when the glucose 
exceeded 215 mg/dl and titrated to keep levels between 180 
and 200 mg/dl. Renal dysfunction was specified by compari-
son of peak and baseline creatinine levels. Risk was defined 
as a peak of 1.5–1.99 times higher than baseline. Injury was 
defined as a peak between 2 and 2.99 times higher than that 
at admission, and failure was defined as a peak greater than 3 
times higher than baseline. Across many end points, the IIT 
group had a significantly lower risk of renal dysfunction com-
pared with the conventional therapy group (Figure). While 
little difference was found between the groups in risk, injury 
and failure were significantly lower in the IIT group com-
pared with the conventional therapy group (3.0% versus 
6.1%, P = 0.03; and 1.5% versus 3.1%, P = 0.005). These dif-
ferences were more pronounced among persons who received 
surgery. Although the differences did not retain statistical 
significance independently among patients admitted to the 
intensive care unit who did not receive surgery, the point esti-
mates suggest a benefit nonetheless. Further, the combined 
end points of injury and failure were significantly different 
among those who did not receive surgery (6.0% versus 9.2%, 
P = 0.04).
Schetz et al. did not definitively hypothesize how these 
results can be interpreted. They speculate that the beneﬁts of 
IIT could be due to either protection of the kidney or preven-
tion of complications. Regardless, the beneﬁt of IIT is con-
sistent across many subgroups in this analysis and therefore 
should be considered in the treatment of critically ill patients 
with acute kidney injury. (J Am Soc Nephrol 2008; 19: 571–578; 
doi:10.1681/ASN.2006101091)
Lynda Szczech
1N Engl J Med 2001; 345: 1359–1367. 2N Engl J Med 2006; 354: 449–461.
Renal replacement therapy in 
patients with acute renal failure
While the dose of hemodialysis given to patients with acute 
renal failure is clearly associated with risk of mortality, ongo-
ing controversy exists regarding how the mode of dialysis and 
diﬀerent types of membranes may also aﬀect mortality in the 
maintenance setting.
Pannu et al. conducted a metaanalysis that combined 30 ran-
domized trials and eight prospective cohort studies regarding the 
provision of dialysis for patients with acute renal failure. When 
continuous renal replacement therapy was compared with inter-
mittent hemodialysis, no signiﬁcant diﬀerence was found for 
all-cause mortality (relative risk (RR) = 1.10, 95% conﬁdence 
interval (CI) = 0.99–1.23) or the need for chronic, long-term 
dialysis among survivors (RR = 0.91, 95% CI = 0.56–1.49). 
Among patients treated with continuous renal replacement ther-
apy, the risk of death was lower at doses greater than 35 ml/kg 
per hour (RR = 0.74, 95% CI = 0.63–0.88) compared with doses 
of 20 ml/kg per hour. The use of unsubstituted cellulosic mem-
branes was associated with a greater risk of death as compared 
with biocompatible membranes among patients receiving inter-
mittent hemodialysis (RR = 1.23, 95% CI = 1.01–1.50). The mes-
sages of this meta-analysis are not surprising; however, given 
the diﬃculty of performing randomized trials among critically 
ill patients with renal failure, this meta-analysis has signiﬁcant 
value for the renal community. While the choice of modality 
was not associated with a diﬀerence in outcomes, a higher dose 
of dialysis was associated with lower mortality in those receiv-
ing continuous renal replacement therapy. Also, although the 
use of biocompatible membranes in intermittent hemodialysis 
has been the subject of conﬂicting research, its association with 
lower mortality in this study may be useful in establishing clear-
ance goals for patients receiving continuous renal replacement 
therapy. (JAMA 2008; 299: 793–805)
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Oliguria
Impact of IIT versus conventional treatment on the incidence of 
different renal outcome categories in surgical and medical (non-
surgical) patients. *P < 0.05; **P < 0.01. mR-R, modified risk–RIFLE 
(risk, injury, failure, loss, end-stage renal disease); mR-I, modified 
risk–injury; mR–F, modified risk–failure; mR–IF, modified risk–injury 
and failure; RRT, renal replacement therapy; AKI, acute kidney injury.
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